nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

05.01.2024 | short review

Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach

verfasst von: Dr. Katja Schmitz

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Summary

The biomarker developments in adenocarcinomas of the esophagus, gastroesophageal junction, and stomach are currently very exciting. Clinical trial data for Claudin 18.2 and FGFR2b are promising and EMA approvals are expected. Routine testing includes PD-L1, HER2, and MSI.

Vorheriger Artikel Innovative therapeutic concepts for biliary tumors

Nächster Artikel Cancer of unknown primary—state of the art

access: 05.05.2023.. https://clinicaltrials.gov/..

Athauda, A., et al. Claudin 18.2‑a FAST-moving target in gastric cancer?. Annals of oncology: official journal of the European Society for Medical Oncology (2021) 32(5), 584–586. https://doi.org/10.1016/j.annonc.2021.02.021

Cao W, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38. https://doi.org/10.1186/s40364-022-00385-1.MathSciNetCrossRefPubMedPubMedCentral

Shitara, K., et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). J Clin Oncol 41, 2023 (suppl 16; abstr 4035); https://doi.org/10.1200/JCO.2023.41.16_suppl.4035

Shitara, K., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2‑positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet (2023).

Pellino A, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. JPM. 2021;11(11):1095.CrossRefPubMedPubMedCentral

Klempner SJ, et al. FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a. Distinct Genomic Landsc. 2019;.

Wainberg, Z. A., et al. (2022). Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. Oncology, 23(11), 1430–1440. https://doi.org/10.1016/S1470-2045(22)00603‑9

Gordon A, et al. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. OTT. 2022; 1183–96.

10.

Shitara K, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.CrossRefPubMed

11.

Seo, S., et al. (2017). Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).

12.

Ruschoff, J., et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol (2023) 25(5):637–50.

13.

Yamaguchi K, et al. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol. 2020;31:S899–S900.CrossRef

14.

Alsina M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155–70. https://doi.org/10.1038/s41575-022-00703-w.CrossRefPubMed

15.

Schildhaus HU. Der prädiktive Wert der PD-L1-Diagnostik. Pathologe. 2018;39:498–519. https://doi.org/10.1007/s00292-018-0507-x.CrossRefPubMed

16.

European Commission approved Merck’s Keytruda (pembrolizumab) for patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in five different types of cancer. News Release. Merck. April 29. 2022. https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-deficient-mismatch-repair-dmmr-tumors-in-five-different-types/. Accessed 12 Dec 2023.

17.

Stolze T, et al. Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. J Cancer Res Clin Oncol. 2023;149:1007–17. https://doi.org/10.1007/s00432-022-03953-y.CrossRefPubMed

18.

Puhr, H.C., et al. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers 2021, 13, 4632. https://doi.org/10.3390/cancers13184632

19.

Högner A, et al. Immunotherapy in Gastric Cancer. Curr Oncol. 2022;29:1559–74. https://doi.org/10.3390/curroncol29030131.CrossRefPubMedPubMedCentral

Titel: Molecular typing—new targets and therapy options for upper GI carcinomas with a focus on adenocarcinomas of the esophagus, gastroesophageal junction, and stomach
verfasst von: Dr. Katja Schmitz
Publikationsdatum: 05.01.2024
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00950-w

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

OeGHO annual meeting 2023—best of oncology

Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review

Management of oligometastatic prostate cancer

(Neo)adjuvant approaches: pavement on the road to cure—breast cancer

Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule

“Navigating the evolving landscape of cancer treatment: a triad of progress”